GW Pharmaceuticals PLC Notice of Results (6658N)
July 30 2014 - 2:02AM
UK Regulatory
TIDMGWP
RNS Number : 6658N
GW Pharmaceuticals PLC
30 July 2014
GW Pharmaceuticals to Report Q3 2014 Financial Results and Host
Conference Call
on 6 August, 2014
London, UK, 30 July 2014: GW Pharmaceuticals plc (Nasdaq: GWPH,
AIM: GWP, "GW" or "the Company"), a biopharmaceutical company
focused on discovering, developing and commercializing novel
therapeutics from its proprietary cannabinoid product platform,
will announce on 6 August, 2014 its third quarter financial results
for the period ending 30 June, 2014. GW will also host a conference
call the same day at 1:00 p.m. BST (8:00 a.m. EDT).
Conference call information will be provided in the financial
results press release. A replay of the call will also be available
through the Company's website (www.gwpharm.com) shortly after the
call.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex(R), which is approved for
the treatment of spasticity due to multiple sclerosis in 25
countries outside the United States. Sativex is also in Phase 3
clinical development as a potential treatment of pain in people
with advanced cancer. This Phase 3 program is intended to support
the submission of a New Drug Application for Sativex in cancer pain
with the U.S. Food and Drug Administration and in other markets
around the world. GW has a deep pipeline of additional cannabinoid
product candidates, including Epidiolex which has received from the
FDA Fast Track Designation for the treatment of Dravet syndrome and
Orphan Drug Designation from the FDA for the treatment of Dravet
and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy
syndromes. GW's product pipeline also includes compounds in Phase 1
and 2 clinical development for glioma, ulcerative colitis, type-2
diabetes, and schizophrenia. For further information, please visit
www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc
(Today) +44 20 3727 1000
Justin Gover, CEO
+44 1980 557000
Stephen Schultz, VP Investor Relations
+ 1 401 500 6570 or + 1 917 280 2424
FTI Consulting
Ben Atwell / Simon Conway / John Dineen (European media
enquiries)
+ 44 20 3727 1000
Robert Stanislaro (US media enquiries)
+1 212 850 5657
Trout Group, LLC (US investor relations)
Todd James / Chad Rubin
+1 646 378 2900
Peel Hunt LLP (UK Nominated Adviser and Broker)
James Steel / Oliver Jackson
+44 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORQKLFLZDFXBBL
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024